JP2023501347A - アレルギー性疾患を治療するためのＦｃεＲＩβ及びＭＳ４Ａ６Ａを組み合わせたエクソンスキップ - Google Patents

アレルギー性疾患を治療するためのＦｃεＲＩβ及びＭＳ４Ａ６Ａを組み合わせたエクソンスキップ Download PDF

Info

Publication number
JP2023501347A
JP2023501347A JP2022526035A JP2022526035A JP2023501347A JP 2023501347 A JP2023501347 A JP 2023501347A JP 2022526035 A JP2022526035 A JP 2022526035A JP 2022526035 A JP2022526035 A JP 2022526035A JP 2023501347 A JP2023501347 A JP 2023501347A
Authority
JP
Japan
Prior art keywords
sequence
ms4a6a
fcεriβ
exon
antisense oligomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022526035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023501347A5 (https=
Inventor
ピー クルース グレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North Carolina State University
Original Assignee
North Carolina State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Carolina State University filed Critical North Carolina State University
Publication of JP2023501347A publication Critical patent/JP2023501347A/ja
Publication of JP2023501347A5 publication Critical patent/JP2023501347A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022526035A 2019-11-08 2020-11-09 アレルギー性疾患を治療するためのＦｃεＲＩβ及びＭＳ４Ａ６Ａを組み合わせたエクソンスキップ Pending JP2023501347A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962932664P 2019-11-08 2019-11-08
US62/932,664 2019-11-08
PCT/US2020/059682 WO2021092562A1 (en) 2019-11-08 2020-11-09 Exon skipping of fc-epsilon-ri-beta and ms4a6a in combination for the treatment of allergic diseases

Publications (2)

Publication Number Publication Date
JP2023501347A true JP2023501347A (ja) 2023-01-18
JP2023501347A5 JP2023501347A5 (https=) 2023-11-16

Family

ID=75849333

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526035A Pending JP2023501347A (ja) 2019-11-08 2020-11-09 アレルギー性疾患を治療するためのＦｃεＲＩβ及びＭＳ４Ａ６Ａを組み合わせたエクソンスキップ

Country Status (6)

Country Link
US (1) US20220380777A1 (https=)
EP (1) EP4054639A4 (https=)
JP (1) JP2023501347A (https=)
CN (1) CN115335078A (https=)
AU (1) AU2020378207A1 (https=)
WO (1) WO2021092562A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136435A1 (en) 2016-02-01 2017-08-10 The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health Compounds for modulating fc-epsilon-ri-beta expression and uses thereof
CN112023062A (zh) * 2020-09-18 2020-12-04 北京基因安科技有限公司 一个用可溶性IgE受体抑制过敏反应的方法
CN120019145A (zh) * 2022-09-28 2025-05-16 阿塔兰塔治疗公司 用于治疗神经炎性疾病的组合物和方法
CN116219009B (zh) * 2022-10-19 2024-10-01 杭州师范大学 小胶质细胞特异性表达的ms4a6a在胶质母细胞瘤治疗或预后评估试剂盒上的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103074422A (zh) * 2012-12-29 2013-05-01 深圳市第三人民医院 Ms4a6a基因的用途
CN105969901A (zh) * 2016-07-27 2016-09-28 北京泱深生物信息技术有限公司 Ms4a6a作为多发性骨髓瘤诊治标志物的用途
WO2017136435A1 (en) * 2016-02-01 2017-08-10 The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health Compounds for modulating fc-epsilon-ri-beta expression and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040137566A1 (en) * 2001-12-10 2004-07-15 Tedder Thomas F. Identification of novel ms4a gene family members expressed by hematopoietic cells
EP2933332A1 (en) * 2004-06-28 2015-10-21 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
EP2290087A3 (en) * 2004-12-22 2011-06-15 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
EP3841198A4 (en) * 2018-04-13 2022-03-02 Rene Anand REAGENTS AND METHODS FOR AUTISM AND ITS COMORBIDITIES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103074422A (zh) * 2012-12-29 2013-05-01 深圳市第三人民医院 Ms4a6a基因的用途
WO2017136435A1 (en) * 2016-02-01 2017-08-10 The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health Compounds for modulating fc-epsilon-ri-beta expression and uses thereof
CN105969901A (zh) * 2016-07-27 2016-09-28 北京泱深生物信息技术有限公司 Ms4a6a作为多发性骨髓瘤诊治标志物的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IMMUNOGENETICS, vol. 53, JPN6025021519, 2001, pages 357 - 368, ISSN: 0005822093 *
THE PROCEEDINGS OF THE NATIONALACADEMY OF SCIENCE, vol. 113, no. 49, JPN6025021518, 2016, pages 14115 - 14120, ISSN: 0005608722 *

Also Published As

Publication number Publication date
EP4054639A1 (en) 2022-09-14
EP4054639A4 (en) 2025-04-30
AU2020378207A1 (en) 2022-06-23
WO2021092562A1 (en) 2021-05-14
CN115335078A (zh) 2022-11-11
US20220380777A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
US20230346928A1 (en) Mrna combination therapy for the treatment of cancer
JP2023501347A (ja) アレルギー性疾患を治療するためのＦｃεＲＩβ及びＭＳ４Ａ６Ａを組み合わせたエクソンスキップ
US20230061936A1 (en) Methods of dosing circular polyribonucleotides
KR102825946B1 (ko) IL4Rα, TRPA1, 또는 F2RL1을 표적화하는 RNA 복합체를 사용한 아토피 피부염 및 천식의 치료
EP3430143B1 (en) Inhibitors of srsf1 to treat neurodegenerative disorders
JP7479399B2 (ja) 癌腫瘍に対するテーラード低免疫ナノ小胞送達系
US20220241391A1 (en) Methods of blocking asfv infection through interruption of cellular and viral receptor interactions
CN114127301B (zh) 用于治疗肿瘤的药物组合物、药盒和方法
CN112236130A (zh) 使用外排体对癌基因的治疗性靶向
US20220372492A1 (en) Compounds for modulating fc-epsilon-ri-beta expression and uses thereof
CN118043461A (zh) 方法
JPH09501057A (ja) 新規のオリゴヌクレオチド相互作用による血管細胞接着分子の発現の調節
CN113508175A (zh) 用于治疗癌症的组合物和方法
US20220290157A1 (en) Compositions and methods for treating amyotrophic lateral sclerosis
WO2022022617A1 (en) Combinatory treatment of sma with sarna and mrna modulators
WO2021150770A1 (en) Oncogenic trim37 is a targetable epigenetic driver of metastasis and links chemoresistance and metastatic fate in triple-negative breast cancer
RU2839162C2 (ru) Молекула олигомерной нуклеиновой кислоты и ее применение
US20250368713A1 (en) Compositions, systems and methods for manipulating area postrema (ap) neurons based on gfral sensing
US20240425828A1 (en) Targeted retroviral integration for treatment of genetic disorders
TW202606727A (zh) 靶向抑制素亞基βＥ（ＩＮＨＢＥ）的工程化基因轉錄阻抑工具及其用途
HK40092520A (zh) Sarna和mrna调节剂联合治疗sma
WO2025219365A1 (en) Repression of cargo expression
WO2026096962A1 (en) Methods and compounds for treating, ameliorating and/or preventing fibrotic diseases
PT1966368E (pt) Inibição do igf-1r mediada por arni para o tratamento da angiogénese ocular

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20230227

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260324